

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/527,078	11/22/2005	Yuji Ohashi	AOKI-0011	4738
7590 12/28/2007 Millen White Zelano & Branigan			EXAMINER	
Arlington Courthouse Plaza 1 Suite 1400 2200 Clarendon Blvd			KAROL, JODY LYNN	
			ART UNIT	PAPER NUMBER
Arlington, VA	· ·	1617		
			<u> </u>	
			MAIL DATE	DELIVERY MODE
			12/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
Office Action Summary		10/527,078	OHASHI ET AL.		
		Examiner	Art Unit		
•		Jody L. Karol	1617		
	The MAILING DATE of this communication app				
Period fo					
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1)[]	Responsive to communication(s) filed on 09 M	arch 2005.			
2a) <u></u> □	This action is FINAL . 2b) This action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.		
Dispositi	on of Claims				
5) 6) 7)	Claim(s) 1-22 is/are pending in the application. 4a) Of the above claim(s) is/are withdrav Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) -122 are subject to restriction and/or expressions.	vn from consideration.			
Applicati	on Papers				
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accentified accentifi	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	ınder 35 U.S.C. § 119	•			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachmen		_			
2) Notic 3) Infor	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite		

Application/Control Number:

10/527,078 Art Unit: 1617

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-6, drawn to a whitening agent comprising a crystalline molecular complex composed of hydroquinone or a derivative thereof and a surfactant.

Group II, claims 7-12, drawn to the use of a crystalline molecular complex composed of hydroquinone or a derivative thereof and a surfactant for production of a whitening agent.

Group III, claims 13-18, drawn to a whitening method for skin wherein a whitening agent comprising a crystalline molecular complex composed of hydroquinone or a derivative thereof and a surfactant is applied to pigmented skin.

Group IV, claims 19-22, drawn to a process for production of a whitening agent.

2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features.

An international application should relate to only one invention or, if there is more than one invention, the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept (PCT Rule 13.1). With respect to a group of inventions claimed in an

10/527,078 Art Unit: 1617

international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features.

The expression "special technical features" is defined in PCT Rule 13.2 as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art. The determination is made on the contents of the claims as interpreted in light of the description and drawings (if any). Whether or not any particular technical feature makes a "contribution" over the prior art, and therefore constitutes a "special technical feature," should be considered with respect to novelty and inventive step.

The common technical feature among the groups is a crystalline molecular complex composed of hydroquinone or a derivative thereof and a surfactant. The complex cannot be considered a special technical feature because it is known in the prior art. For example, Ohashi et al. (JP 2001-302576 A) teaches a method of adjusting the evaporation rate of an aromatic comprising forming crystals of a molecular complex of an aromatic compound (see abstract). Ohashi et al. further teaches that acceptable aromatic compounds include a hydroquinone (see section [0018]. Accordingly, the unity of invention is considered to be lacking, and restriction in accordance with the rules of unity of invention is considered proper.

10/527,078 Art Unit: 1617

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- a. Hydroquinone and derivatives (i.e. hydroquinone, hydroquinone monobenzyl ether, etc.)
- b. Surfactants (i.e. STAB, STAC, CTAB, etc.)

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 4. The claims are deemed to correspond to the species listed above in the following manner:
 - i. Claims 2-3, 8-9, and 14-15 correspond to species of hydroquinone and derivatives.
 - ii. Claims 4-6, 10-12, and 16-18 correspond to species of surfactants.

Application/Control Number:

10/527,078 Art Unit: 1617

The following claim(s) are generic: 1, 7, 13, and 19-22.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species of hydroquinone derivatives and surfactants are known. Ohashi et al. teaches hydroquinone and several species of surfactants (see sections [0012] to [0013] and the Example in [0021] to [0022]).

5. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

10/527,078

Art Unit: 1617

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jody L. Karol whose telephone number is (571) 270-3283. The examiner can normally be reached on 8:30 am - 5:00 pm Mon-Fri EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/527,078 Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JLK

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER